Azf is scheduled to organize production and supply by real biology in China.

Author:Red Star News Time:2022.07.27

Red Star Capital Bureau July 27th news, Real Biotechnology Co., Ltd. (hereinafter referred to as "real creature") last night, Fosun Pharmaceutical (600196.SH; 02196.HK) exclusive commercial Azf's cooperative area of Azf's cooperation area In China, it is mainly responsible for organizing the production and supply of cooperative products by real creatures.

On July 27th, about the scale of the exclusive commercialization of Azfdin in China, the Secretary of the Fosun Pharmaceuticals told the Red Star Capital Bureau, "We are still in the process of product diligence, and there may be more detailed supplementary agreements in the future. come out."

Yesterday, the results of Fosun Pharmaceutical's fixed increase also settled. Among them, Feng Liu managed Gao Yishan No. 1 Yuanwang Fund's distribution of nearly 2 billion yuan, ranking first. After the issuance was completed, Gao Yi assets jumped into the third largest shareholder of Fosun Pharmaceutical.

Fosun Pharmaceutical Exclusive Commercial Azfdin

The real creatures in China are mainly responsible for organizing production and supply

The cooperation between Fosun Pharmaceutical and real creatures has more detailed information.

On the evening of July 26, a strategic cooperation announcement between the real creatures and Fosun Pharmaceutical stated that the two parties will jointly develop and be exclusively commercialized by Fosun Pharmaceutical Holding subsidiaries. The field of AIDS treatment and prevention.

Both parties will rely on their respective advantages to carry out commercial cooperation in China (excluding Hong Kong, Macao and Taiwan) and the global region (excluding Russia, Ukraine, Brazil, and other South American countries and regions in the future of China. Among them, the production and supply of cooperative products in China is mainly responsible for the production and supply of products in China.

In the previous cooperation agreement between Fosun Pharmaceutical's announcement, it did not disclose the specific scale of the exclusive commercialization of Azfdin in China in China.

On July 27, the Red Star Capital Bureau contacted the Fosun Pharmaceutical Secretary Office. Regarding the question of whether Azf's design and supply is mainly responsible for production and supply in China, the staff of the Fosun Pharmaceutical Secretary Office is not positively positive The response only said that "we are still in the process of product diligence, there may be more detailed supplementary agreements in the future." On the same day, the Red Star Capital Bureau opened contact information to the real creature.

However, the two parties have specific negotiations on the distribution of sales profits of Azfdin in China: According to the different sales channels, Fosun Pharmaceutical Industry and real creatures are based on 50%: 50%or 55%: 45%. distribute.

In addition, it is worth mentioning that the second day of the exclusive commercial cooperation between Fosun Pharmaceutical and Real Biological Officers, Fosun Pharmaceutical A shares closed up 3.11%.

4.4 billion fixed decision

Gao Yi Assets becomes the third largest shareholder

In addition to the real creature of "holding hands", Fosun Pharmaceuticals settled yesterday.

According to disclosure, Fosun Pharmaceutical's actual number of issuances this time is about 107 million shares, the issuance price is 42 yuan/share, and the net raised funds are 4.456 billion yuan.

The 10 objects of Fosun Pharmaceutical's non-public distribution, including Shanghai Gaoyi Asset Management Partnership (Limited Partnership) -Gaoyi Neighborhood No. 1 Yuanwang Fund, CITIC Securities, Huatai Securities, Guotai Junan, Huaxia Fund, etc.

Among them, Gao Yishan, managed by the fund manager Feng Liu, received nearly 2 billion yuan from Yuanwang Fund, ranked first. After the issuance was completed, Gao Yi assets jumped to the third largest shareholder of Fosun Pharmaceutical, with a shareholding ratio of 1.78%. In addition, UBS AG and Caitong Fund are the third and ninth shareholders of Fosun Pharmaceutical, respectively, with a shareholding ratio of 0.75%and 0.51%, respectively.